Managing interstitial lung disease detected on CT during lung cancer screening

ABSTRACT
As long-term smokers undergo computed tomography (CT) to screen for lung cancer, cases of interstitial lung disease are being discovered incidentally. This article explains how to distinguish among the most common forms of interstitial lung disease in this situation and the role of primary care physicians in managing them.

KEY POINTS
Smoking-related interstitial lung diseases can broadly be categorized as fibrotic or nonfibrotic on the basis of their appearance on CT. Fibrotic disease generally carries a worse prognosis.

Nonfibrotic interstitial lung diseases include respiratory bronchiolitis, respiratory bronchiolitis-interstitial lung disease, desquamative interstitial pneumonia, and pulmonary Langerhans cell histiocytosis.

Smoking-related fibrotic interstitial lung diseases include nonspecific interstitial pneumonia and usual interstitial pneumonia. A subset of usual interstitial pneumonia, called idiopathic pulmonary fibrosis, carries the worst prognosis of all.

If CT detects interstitial lung disease during screening for lung cancer, the clinician should strongly consider further evaluation with dedicated high-resolution CT and early referral to a specialist. Smoking cessation is extremely important.

doi:10.3949/ccjm.83a.14157
### TABLE 1

**Features of nonfibrotic smoking-related interstitial lung disease**

<table>
<thead>
<tr>
<th></th>
<th>Respiratory bronchiolitis</th>
<th>Respiratory bronchiolitis-interstitial lung disease</th>
<th>Desquamative interstitial pneumonia</th>
<th>Pulmonary Langerhans cell histiocytosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Zonal distribution</strong></td>
<td>Upper lobe</td>
<td>Upper lobe</td>
<td>Lower lobe (60%)</td>
<td>Upper lobe (spares the costophrenic angles)</td>
</tr>
<tr>
<td><strong>Clinical findings</strong></td>
<td>Absent</td>
<td>Cough and dyspnea</td>
<td>Cough and dyspnea</td>
<td>Cough and dyspnea, constitutional symptoms (1/3 of patients) and pneumothorax (15%)</td>
</tr>
<tr>
<td><strong>Findings on high-resolution computed tomography</strong></td>
<td>Poorly defined centrilobular ground-glass nodules</td>
<td>Poorly defined centrilobular ground-glass nodules</td>
<td>Ground-glass opacity (widespread, bilateral and symmetrical in 86%)</td>
<td>Cysts: bizarrely shaped and nonuniform in size</td>
</tr>
<tr>
<td></td>
<td>Patchy ground-glass opacities</td>
<td>Bronchial wall thickening</td>
<td>Reticular opacities (59%)</td>
<td>Nodules: irregular or cavitary, centrilobular and peribronchial in location</td>
</tr>
<tr>
<td></td>
<td>Bronchial wall thickening</td>
<td>Reticulation occasionally (no traction bronchiectasis or honeycombing)</td>
<td>Traction bronchiectasis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Honeycombing is uncommon (&lt; 1/3 of patients)</td>
<td></td>
</tr>
<tr>
<td><strong>Associated features</strong></td>
<td>Centrilobular emphysema</td>
<td>Centrilobular emphysema</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Air-trapping</td>
<td>Periferal cystic spaces (dilated bronchioles and alveolar ducts)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Characteristic image</strong></td>
<td>Figure 1</td>
<td>Figure 2</td>
<td>Figures 3 and 4</td>
<td>Figures 5–8</td>
</tr>
<tr>
<td><strong>Typical clinical course</strong></td>
<td>Usually asymptomatic; may progress to respiratory bronchiolitis-interstitial lung disease if smoking continues</td>
<td>Cough and progressive dyspnea on exertion</td>
<td>Cough and progressive dyspnea; can progress despite smoking cessation</td>
<td>Fever, weight loss, nonproductive cough, dyspnea, chest pain; spontaneous pneumothorax also seen</td>
</tr>
<tr>
<td><strong>Role of lung biopsy</strong></td>
<td>None</td>
<td>None</td>
<td>Surgical lung biopsy may be indicated if diagnosis is uncertain</td>
<td>Surgical lung biopsy may be indicated if diagnosis is uncertain</td>
</tr>
</tbody>
</table>
lung diseases the internist may encounter on screening CT in long-term smokers.

Referral to a specialist has been associated with lower rates of morbidity and death, and a diagnosis of interstitial lung disease should be confirmed by a pulmonologist and a radiologist specializing in differentiating the subtypes. But the primary care physician now plays a critical role in recognizing the need for further evaluation.

**HOW COMMON IS INTERSTITIAL LUNG DISEASE IN SMOKERS?**

Several studies have published data on the prevalence of interstitial lung disease in patients undergoing low-dose CT for lung cancer screening. A trial at Mayo Clinic in current and former smokers identified “diffuse lung disease” in 9 (0.9%) of 1,049 participants.
A trial in Ireland identified idiopathic pulmonary fibrosis in 6 (1.3%) of 449 current smokers who underwent low-dose CT screening for lung cancer.\(^7\)

Sverzellati et al\(^8\) evaluated 692 participants in the Multicentric Italian Lung Detection CT screening study and reported a respiratory bronchiolitis pattern in 109 (15.7%), a usual interstitial pneumonia pattern in 2 (0.3%), and other patterns of chronic interstitial pneumonia in 26 (3.8%).

The National Lung Screening Trial reported that the frequency of “clinically significant” incidental findings (including pulmonary fibrosis) in all participants was 7.5%.\(^1\) A retrospective analysis of 884 participants at a single site in this trial identified interstitial lung abnormalities in 86 participants (9.7%).\(^9\) These abnormalities were further categorized as nonfibrotic in 52 (5.9%) of 884, fibrotic in 19 (2.1%) of 884, and mixed fibrotic and nonfibrotic in 15 (1.7%) of 884.

Follow-up CT at 2 years in this trial demonstrated improvement in 50% and progression in 11% of patients who had nonfibrotic abnormalities, while fibrotic abnormalities improved in no cases and progressed in 37%. Interstitial lung abnormalities were more common in those who currently smoked and in those with more pack-years of cigarette smoking.\(^9\)

In sum, these trials suggest that low-dose CT screening for lung cancer can detect the most common forms of interstitial lung disease in this at-risk population and can characterize them as fibrotic or nonfibrotic, a distinction important for prognosis and subsequent management.

### NONFIBROTIC VS FIBROTIC DISEASE

It is important to distinguish between nonfibrotic and fibrotic interstitial lung disease, as fibrotic disease carries a worse prognosis and is treated differently.

**Features of nonfibrotic interstitial lung disease:**
- Ground-glass opacities
- Nodules
- Mosaic attenuation or consolidation.
Features of fibrotic interstitial lung disease:
- Combination of ground-glass opacities and reticulation
- Reticulation by itself
- Traction bronchiectasis
- Honeycombing
- Loss of lung volume.

NONFIBROTIC INTERSTITIAL LUNG DISEASES

Given the strong likelihood that a patient undergoing screening CT is either a current or former smoker, physicians may encounter, in addition to emphysema and lung cancer, the following smoking-related interstitial lung diseases, which are primarily nonfibrotic and which frequently coexist (Table 1):
- Respiratory bronchiolitis
- Respiratory bronchiolitis-interstitial lung disease
- Desquamative interstitial pneumonia
- Pulmonary Langerhans cell histiocytosis.

Respiratory bronchiolitis
Respiratory bronchiolitis occurs mostly in smokers and does not necessarily lead to respiratory symptoms in all patients. It cannot always be identified radiographically but occasionally appears as predominantly upper-lobe, patchy ground-glass opacities or ill-defined centrilobular nodules without evidence of fibrosis (Figure 1).

Respiratory bronchiolitis-interstitial lung disease
In rare cases, respiratory bronchiolitis leads to peribronchial fibrosis invading the alveolar walls, which is then classified as respiratory bronchiolitis-interstitial lung disease. The CT findings in respiratory bronchiolitis-interstitial lung disease are upper-lobe-predominant centrilobular ground-glass nodules, patchy ground-glass opacities, and bronchial wall thickening (Figure 2). Occasionally, mild reticulation is noted without honey-

---

### TABLE 2

Features of fibrotic smoking-related interstitial lung disease

<table>
<thead>
<tr>
<th></th>
<th>Nonspecific interstitial pneumonia</th>
<th>Usual interstitial pneumonia, idiopathic pulmonary fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Craniocaudal</strong></td>
<td>Basilar, symmetric</td>
<td>Apicobasal gradient</td>
</tr>
<tr>
<td><strong>Axial distribution</strong></td>
<td>Subpleural and peribronchovascular</td>
<td>Subpleural</td>
</tr>
<tr>
<td><strong>Morphology</strong></td>
<td>Ground-glass opacities (80%)</td>
<td>Reticulation (coarse)</td>
</tr>
<tr>
<td></td>
<td>Subpleural sparing (20%–50%)—most specific</td>
<td>Honeycombing (up to 70%)</td>
</tr>
<tr>
<td></td>
<td>Reticulation (fine or coarse)</td>
<td>Traction bronchiectasis</td>
</tr>
<tr>
<td></td>
<td>Traction bronchiectasis</td>
<td>Ground-glass opacities in regions of fibrosis, less extensive than the reticulation</td>
</tr>
<tr>
<td></td>
<td>Consolidation</td>
<td>Architectural distortion</td>
</tr>
<tr>
<td></td>
<td>Honeycombing (uncommon, 1%–5%)</td>
<td></td>
</tr>
<tr>
<td><strong>Characteristic image</strong></td>
<td>Figures 9–12</td>
<td>Figures 13 and 14</td>
</tr>
<tr>
<td><strong>Typical clinical course</strong></td>
<td>Progressive dyspnea, cough, and hypoxemia; often have extrapulmonary manifestations (eg, joint pain, rash, Raynaud phenomenon); may respond to immunosuppressive therapy, especially if ground-glass opacities are present</td>
<td>Progressive dyspnea, cough, and hypoxemia; newly approved antifibrotic agents may slow progression of disease</td>
</tr>
<tr>
<td><strong>Role of lung biopsy</strong></td>
<td>Surgical lung biopsy may be indicated if diagnosis is uncertain</td>
<td>Surgical lung biopsy may be indicated if diagnosis is uncertain</td>
</tr>
</tbody>
</table>
It is important to distinguish between nonfibroitic and fibrotic interstitial lung disease.

**Pulmonary Langerhans cell histiocytosis**

The combination of upper-lobe-predominant cysts and nodules in a young heavy smoker are diagnostic of pulmonary Langerhans cell histiocytosis. The cysts are bizarrely shaped, thin- or thick-walled, and nonuniform in size (Figure 5). The irregular cavitary nodules are centrilobular. The disease characteristically spares the costophrenic angles.

Spontaneous pneumothorax is the initial clinical presentation in 15% of patients.16 In the early stages of the disease (nodule-predominant disease without cysts), infection and metastatic disease need to be excluded (Figure 6). In the later stages, the cysts become coalescent, making the distinction between this disease and “burned-out” lymphangioleiomyomatosis or severe emphysema extremely difficult (Figure 7).17

Smoking cessation and corticosteroids are the mainstay of medical therapy for pulmonary Langerhans cell histiocytosis, and about 50% of patients who quit smoking and receive corticosteroids demonstrate partial or complete clearing of the radiographic abnormalities and symptoms (Figure 8).

dilated bronchioles and alveolar ducts rather than honeycombing.16

No additional treatment beyond elimination of smoking has been proven effective for desquamative interstitial pneumonia, and patients who manage to quit smoking generally have a favorable prognosis.17,18

**Pulmonary Langerhans cell histiocytosis**

The combination of upper-lobe-predominant cysts and nodules in a young heavy smoker are diagnostic of pulmonary Langerhans cell histiocytosis. The cysts are bizarrely shaped, thin- or thick-walled, and nonuniform in size (Figure 5). The irregular cavitary nodules are centrilobular. The disease characteristically spares the costophrenic angles.

Spontaneous pneumothorax is the initial clinical presentation in 15% of patients.16 In the early stages of the disease (nodule-predominant disease without cysts), infection and metastatic disease need to be excluded (Figure 6). In the later stages, the cysts become coalescent, making the distinction between this disease and “burned-out” lymphangioleiomyomatosis or severe emphysema extremely difficult (Figure 7).17

Smoking cessation and corticosteroids are the mainstay of medical therapy for pulmonary Langerhans cell histiocytosis, and about 50% of patients who quit smoking and receive corticosteroids demonstrate partial or complete clearing of the radiographic abnormalities and symptoms (Figure 8).
If CT identifies a diffuse fibrotic pattern, the two most common possibilities (Table 2) are:

- Nonspecific interstitial pneumonia
- Usual interstitial pneumonia.

As noted above, these carry a worse prognosis than the nonfibrotic interstitial lung diseases.

### Nonspecific interstitial pneumonia

While most frequently idiopathic, the nonspecific interstitial pneumonia pattern can often be seen in connective tissue diseases. It has also been associated with chronic hypersensitivity pneumonitis, drug toxicity, and slowly resolving diffuse alveolar damage.\(^{19}\) Although it is not the only pathologic pattern in interstitial lung disease associated with connective tissue disease, it is the most common pattern in systemic sclerosis, systemic lupus erythematosus, dermatomyositis-polymyositis, and mixed connective tissue disease.\(^{20}\)

The parenchymal changes are typically subpleural and symmetric in distribution (Figure 9). In about one-third of cases, there is a peribronchovascular distribution of the abnormalities (Figure 10).

Ground-glass opacities are the dominant imaging findings, seen in 80% of cases.\(^{18}\) In advanced disease (also referred to as fibrotic nonspecific interstitial pneumonia), patients have accompanying fine or coarse reticular opacities, traction bronchiectasis, and consolidation (Figure 11). Honeycombing is seen in 1% to 5% of patients.\(^{21}\)

The most specific sign of nonspecific interstitial pneumonia is sparing of the immediate subpleural lung, apparent in 30% to 50% of patients (Figure 12).\(^{22}\) Subpleural sparing with a peribronchovascular distribution of abnormalities, absence of lobular areas with decreased attenuation, and lack of honeycombing are imaging features that increase the diagnostic confidence of nonspecific interstitial pneumonia (Table 3).\(^{23}\) Clinically, compared with those who have usual interstitial pneumonia (see below), patients are younger and more of them are female. These patients also present with extrapulmonary manifestations such as joint involvement, rash, and Raynaud phenomenon. Therefore, these associated symptoms on presentation can help distinguish nonspecific interstitial pneumonia or usual interstitial pneumonia related to connective tissue disease from the idiopathic forms.

The first step in managing nonspecific interstitial pneumonia is to remove all potential exposure to inhaled substances or to drugs. Although immunosuppressive therapy has never been studied in a randomized controlled trial in this disease, numerous reports suggest that patients may respond to prednisone and to steroid-sparing immunosuppressants.\(^{24}\)
In several studies, survival rates in nonspecific interstitial pneumonia were significantly greater than in usual interstitial pneumonia independent of the treatment strategy. In long-term follow-up of patients with idiopathic nonspecific interstitial pneumonia treated with immunosuppressive therapy, two-thirds remained stable or improved.25–27 Although most connective tissue diseases cause a lung pattern of nonspecific interstitial pneumonia, some (eg, rheumatoid arthritis) may present with a pattern of usual interstitial pneumonia. In these cases and in those of advanced fibrotic nonspecific interstitial pneumonia, the prognosis is worse, as the disease is less responsive to immunosuppressive therapy.20

Usual interstitial pneumonia
Usual interstitial pneumonia is the most severe form of lung fibrosis. Most cases are idiopathic and are termed idiopathic pulmonary fibrosis. Other causes of the usual interstitial pneumonia pattern include domestic and occupational environmental exposures, connective tissue disease, and drug toxicity.28 An epidemiologic association between smoking and usual interstitial pneumonia is well documented.28

Idiopathic pulmonary fibrosis typically affects men ages 50 to 70. Because its risk factors coincide with those of lung cancer, there is a high likelihood of detecting idiopathic pulmonary fibrosis early in this screening population. It has an especially poor prognosis, with a mean survival of 2 to 5 years from the time of diagnosis.18

The distribution of disease in usual interstitial pneumonia is characteristically subpleural and basal. CT features include coarse subpleural reticulation and honeycombing combined with traction bronchiectasis or bronchiolectasis and architectural distortion (Figure 13).18 Honeycombing is the most specific and key diagnostic CT finding for establishing a definitive diagnosis of usual interstitial pneumonia.29 However, ground-glass opacities are present in most patients, typically in the region of interstitial fibrosis, and are always less extensive than the reticulation.30 The findings demonstrate morphologic heterogeneity, with areas of fibrosis adjacent to areas of normal lung (Figure 14).

In addition to the aforementioned imaging features, the 2011 American Thoracic Society and European Respiratory Society joint guidelines for the CT diagnosis of usual interstitial pneumonia patterns require the absence of
atypical features that suggest an alternative diagnosis, including those seen in nonspecific interstitial pneumonia, such as an upper, mid-lung, or peribronchovascular distribution and extensive ground-glass attenuation. Mild mediastinal lymphadenopathy (usually < 1.5 cm in the short axis) is common in usual interstitial pneumonia.

Because other chronic interstitial pneumonias that may resemble usual interstitial pneumonia have a more favorable course and may respond to immunosuppressive therapy, establishing an early and accurate diagnosis is of the utmost importance. Additionally, the emergence of possible new therapies for idiopathic pulmonary fibrosis makes early referral to a specialist paramount in these cases. Recent studies have demonstrated significant slowing of the progression of disease in idiopathic pulmonary fibrosis with both pirfenidone and nintedanib.

**DIAGNOSIS AND MANAGEMENT**

The diagnosis of these nonfibrotic and fibrotic lung diseases is complex. In all cases in which interstitial lung disease is detected on screening CT for lung cancer, the internist should strongly consider further evaluation with dedicated high-resolution CT and early referral to a specialist.

Because smoking cessation is the only recommended treatment for nonfibrotic smoking-related interstitial lung diseases, particular emphasis on smoking cessation counseling is essential.

Referral for bronchoscopy with transbronchial lung biopsy is generally not helpful in...
the diagnosis of the interstitial lung diseases discussed in this article unless there is a need to rule out infection or neoplasm. Referral for surgical lung biopsy may be indicated in some cases of suspected pulmonary Langerhans cell histiocytosis, desquamative interstitial pneumonia, nonspecific interstitial pneumonia, or usual interstitial pneumonia if the diagnosis is uncertain (Tables 1 and 2).

The American Thoracic Society/European Respiratory Society guidelines suggest a multidisciplinary team approach that includes a pathologist, radiologist, and clinician. This approach more readily determines the correct diagnosis and relies less on invasive methods such as surgical biopsy and more on noninvasive methods such as radiology and clinical history. Overall, this will promote earlier access to appropriate therapies, clinical trial enrollment, and in more severe cases, lung transplant.

Currently, 23% of all lung transplants worldwide are performed in patients with idiopathic pulmonary fibrosis. Other forms of pulmonary fibrosis account for 3% to 4% of lung transplants performed.

Evidence suggests that early referral reduces rates of morbidity and death in these patients. The results of a single-center study of patients with idiopathic pulmonary fibrosis demonstrated that a longer delay from the onset of symptoms to evaluation by a specialist at a tertiary care referral center was associated with a higher rate of death from this disease independent of disease severity. Those with the longest delay in referral had a multivariable-adjusted death rate 3.4 times higher than those with the shortest delay.

In summary, with implementation of the new lung cancer screening guidelines, primary care physicians are more often encountering the incidental finding of interstitial lung disease in their patients. Prompt diagnosis of interstitial lung disease helps ensure that patients receive appropriate care and early consideration for clinical trials and lung transplant.

Primary care physicians play a critical role in the initial identification of key characteristics of the interstitial abnormality—namely, whether the pattern is nonfibrotic or fibrotic—and in the correlation of the history and
physical findings to expedite the diagnosis. Subsequently, ordering high-resolution CT for more detailed characterization and prompt referral to a specialist in interstitial lung disease allows for a more rapid and accurate diagnosis, specialized therapy, and supportive care.

**REFERENCES**


**ADDRESS:** Brian D. Southern, MD, Respiratory Institute, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: southeb@ccf.org